An interventional study of Remimazolam and Dexmedetomidine in OSAS (Obstructive Sleep Apneas Syndrome), DISE and Sedation, sponsored by Fu Jen Catholic University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Fu Jen Catholic University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Sleep Apnea, Obstructive with a site in Taiwan — 26 open to participants now, 27 under way, 3 of them phase 3. Sleep Apnea, Obstructive · Taiwan.
Among the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, this one is the 33rd largest by planned enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2026, is one of 51 with no phase, reaches primary completion later than 13 of the 26 other live ones, and was the 82nd registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →26 of the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 4–18
National Sun Yat-sen University · Sites in Taiwan
Ages 20–80
National Sun Yat-sen University · Sites in Taiwan
Ages 20+
Novo Nordisk A/S · Sites in Taiwan, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Taiwan, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 71 across the 58 interventional studies, 103 across the 32 observational. Of the 38 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 90 have an industry lead sponsor. The 10 most frequent:
Fu Jen Catholic University Hospital is the lead sponsor of 33 studies on the registry; 18 are open to participants now.
Fu Jen Catholic University Hospital has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Sleep Apnea, Obstructive with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06854497Chiayi Christian HospitalThe Impact of Non-motor Symptom on the Outcome of Stroke Subjects | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
| NCT06115018Yi-Ju, LaiThe Efficacy and Maintain Effect of OPR on OSA Patients After Palatal Surgery | 2026-12-31 |
| NCT07192042Taipei Medical University Shuang Ho HospitalInvestigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizophrenia | 2027-04-30 |
| NCT07805486Fu Jen Catholic UniversityDevelopment of a Multimodal Deep Learning Model for Pediatric Patients | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with obsturctive sleep apne syndrome receiving dexmedetomidine for sedation during drug-induced sleep endoscopy
Drug: Dexmedetomidine
Patients with obsturctive sleep apne syndrome receiving remimazolam for sedation during drug-induced sleep endoscopy
Drug: Remimazolam
Patients with obsturctive sleep apne syndrome receiving remimazolam for sedation during drug-induced sleep endoscopy
Patients with obsturctive sleep apne syndrome receiving dexmedetomidine for sedation during drug-induced sleep endoscopy
Apneic events
Apnea event during sedation
Time frame: from start of sedation to outpatient discharge from postoperative care unit
Bradycardia
Heart rate less than 60 beats per minute during sedation
Time frame: from start of sedation to outpatient discharge from postoperative care unit
Hypotension
Hypotensive event (defined as less mean blood pressure less than 80% of preoperative mean blood pressure) during sedation
Time frame: from start of sedation to outpatient discharge from postoperative care unit
Agitation
Agitation, coughing, involuntary movement during sedation
Time frame: from start of sedation to outpatient discharge from postoperative care unit
Surgeon satisfaction score
Rate of surgeon satisfaction of certain sedation
Time frame: From start of sedation to outpatient discharge from postoperative care unit
Hypoxic event
hypoxic event during sedation
Time frame: From start of sedation to outpatient discharge from postoperative care unit
Top-up requirement
Additional sedative agents given during sedation
Time frame: From start of sedation to outpatient discharge from postoperative care unit
Patient satisfaction score
validated questionnaire regarding anesthesia quality in chinese after sedation for patients
Time frame: Before outpatient discharge from postoperative care unit
VOTE classification prediction
Using electronic stethescope to collect snoring noise and predict VOTE classification
Time frame: Perioperative phase
Plan to share: Undecided
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.
Counting every sponsor, half of 624 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remimazolam
Fu Jen Catholic University Hospital